Entity

Time filter

Source Type

New Philadelphia, PA, United States

The Wistar Institute is a biomedical center, with a focus on cancer research and vaccine development. It is located in the University City section of Philadelphia, Pa. Founded in 1892 as the first independent, nonprofit, biomedical research institute in the country, Wistar has held the Cancer Center designation from the National Cancer Institute since 1972. Wistar has more than thirty laboratories, which are home to three research programs: a gene expression and regulation program, a molecular and cellular oncogenesis program, and a tumor microenvironment and metastasis program. Wikipedia.


Lieberman P.M.,Wistar Institute
Science | Year: 2014

Fifty years after the discovery of Epstein-Barr virus and its association with cancer, a vaccine or therapy for the virus remains elusive. Source


Compositions, e.g., therapeutic agents, and methods are provided for modulating gene and protein expression of Forkhead Box protein 1 (Foxp1). The therapeutic agents include short nucleic acid molecules that modulate gene and protein expression of Forkhead Box protein 1 (Foxp1) expression, viral vectors containing such molecules, T cells transduced with these viruses for adoptive therapies, and any small molecules that bind to and inactivate Foxp1. These compounds and methods have applications in cancer therapy either alone or in combination with other therapies that stimulate the endogenous immune system in the environment of the cancer, e.g., tumor.


Orom U.A.,Max Planck Institute for Molecular Genetics | Shiekhattar R.,Wistar Institute
Cell | Year: 2013

Enhancer-associated long noncoding RNAs act over long distances and across chromosomes to activate transcription at distal promoters. Here, we address the latest advances made toward understanding the role of long noncoding RNA expression and the involvement of these RNAs in enhancer function through association with protein factors and modulation of chromatin structure. © 2013 Elsevier Inc. Source


Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.


Patent
Wistar Institute | Date: 2015-11-19

The present invention embraces methods for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, thumb, finger, and/or palm domain; or FP-pocket, PT-pocket or Th-pocket of telomerase and testing the compound for its ability to modulate the activity of telomerase. Compounds selected for interacting with the T-pocket or Fingers-Palm pocket of telomerase are also provided.

Discover hidden collaborations